Trial Profile
A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms KEYNOTE144
- Sponsors Acerta Pharma
- 12 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.